tiprankstipranks
Advertisement
Advertisement

LBRX Stock Latest News

LB Pharmaceuticals price target raised to $60 from $45 at H.C. Wainwright
The FlyLB Pharmaceuticals price target raised to $60 from $45 at H.C. Wainwright
21h ago
LBRX
LB Pharmaceuticals price target raised to $69 from $45 at Clear Street
PremiumThe Fly
LB Pharmaceuticals price target raised to $69 from $45 at Clear Street
4d ago
LBRX
LB Pharmaceuticals price target raised to $54 from $46 at BMO Capital
PremiumThe Fly
LB Pharmaceuticals price target raised to $54 from $46 at BMO Capital
8d ago
LBRX
LB Pharmaceuticals price target raised to $53 from $40 at Stifel
PremiumThe Fly
LB Pharmaceuticals price target raised to $53 from $40 at Stifel
8d ago
LBRX
LB Pharmaceuticals management to meet with Piper Sandler
PremiumThe Fly
LB Pharmaceuticals management to meet with Piper Sandler
14d ago
LBRX
LB Pharmaceuticals: Strong Balance Sheet, Clear Clinical Milestones Underpin Buy Rating; 12-Month $45 Price Target Reiterated
PremiumRatingsLB Pharmaceuticals: Strong Balance Sheet, Clear Clinical Milestones Underpin Buy Rating; 12-Month $45 Price Target Reiterated
22d ago
LBRX
LB Pharmaceuticals Announces $150 Million Private Placement Financing
Premium
Company Announcements
LB Pharmaceuticals Announces $150 Million Private Placement Financing
27d ago
8K
LBRX
LB Pharmaceuticals announces $150M private placement
Premium
The Fly
LB Pharmaceuticals announces $150M private placement
27d ago
LBRX
LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained
PremiumRatings
LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained
1M ago
LBRX
LB Pharmaceuticals accelerates Phase 3 schizophrenia trial timeline
PremiumCompany Announcements
LB Pharmaceuticals accelerates Phase 3 schizophrenia trial timeline
1M ago
8K
LBRX
LB Pharmaceuticals expects to report results from NOVA-2 clinical trial in 2027
PremiumThe Fly
LB Pharmaceuticals expects to report results from NOVA-2 clinical trial in 2027
1M ago
LBRX
Shopify downgraded, Five Below upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Shopify downgraded, Five Below upgraded: Wall Street’s top analyst calls
1M ago
GS
RL
LB Pharmaceuticals initiated with an Outperform at BMO Capital
PremiumThe FlyLB Pharmaceuticals initiated with an Outperform at BMO Capital
1M ago
LBRX
LB Pharmaceuticals initiated with an Outperform at Wolfe Research
Premium
The Fly
LB Pharmaceuticals initiated with an Outperform at Wolfe Research
2M ago
LBRX
Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102
Premium
The Fly
Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102
2M ago
LBRX
NMRA
LB Pharmaceuticals Stockholders Approve Directors and Auditor
PremiumCompany Announcements
LB Pharmaceuticals Stockholders Approve Directors and Auditor
3M ago
8K
LBRX
Eight new option listings and one option delisting on May 28th
PremiumThe Fly
Eight new option listings and one option delisting on May 28th
3M ago
CEPT
DXYZ
LB Pharmaceuticals initiated with a Buy at Clear Street
PremiumThe Fly
LB Pharmaceuticals initiated with a Buy at Clear Street
3M ago
LBRX
LB Pharmaceuticals: Buy Rating Reiterated, $45 Price Target Maintained on LB-102 Late-Stage Pipeline and Multi-Billion-Dollar Sales Potential
PremiumRatings
LB Pharmaceuticals: Buy Rating Reiterated, $45 Price Target Maintained on LB-102 Late-Stage Pipeline and Multi-Billion-Dollar Sales Potential
3M ago
LBRX
LB Pharmaceuticals price target raised to $37 from $31 at Roth Capital
PremiumThe FlyLB Pharmaceuticals price target raised to $37 from $31 at Roth Capital
3M ago
LBRX
LB Pharmaceuticals reports Q1 EPS (67c), consensus (67c)
Premium
The Fly
LB Pharmaceuticals reports Q1 EPS (67c), consensus (67c)
3M ago
LBRX
LB Pharmaceuticals initiated with a Buy at H.C. Wainwright
Premium
The Fly
LB Pharmaceuticals initiated with a Buy at H.C. Wainwright
4M ago
LBRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >